About AC Immune
AC Immune is a company based in Lausanne (Switzerland) founded in 2003. AC Immune has raised $119.82 million across 9 funding rounds from investors including Lilly, The Michael J. Fox Foundation and BVF Partners. The company has 172 employees as of December 31, 2024. AC Immune offers products and services including Active Immunotherapies, Morphomer Platform, and Supraantigen Platform. AC Immune operates in a competitive market with competitors including BeiGene, Vir Biotechnology, Cidara Therapeutics, BioNTech and Decibel Therapeutics, among others.
- Headquarter Lausanne, Switzerland
- Employees 172 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ac Immune Sa
-
Annual Revenue
$31.01 M (USD)88.28as on Dec 31, 2024
-
Net Profit
-$57.82 M (USD)4.2as on Dec 31, 2024
-
EBITDA
-$57.18 M (USD)2.85as on Dec 31, 2024
-
Total Equity Funding
$119.82 M (USD)
in 9 rounds
-
Latest Funding Round
Not available
-
Investors
Lilly
& 4 more
-
Employee Count
172
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of AC Immune
AC Immune is a publicly listed company on the NASDAQ with ticker symbol ACIU in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of AC Immune
AC Immune offers a comprehensive portfolio of products and services, including Active Immunotherapies, Morphomer Platform, and Supraantigen Platform.
Develops treatments targeting proteins in neurodegenerative diseases.
Facilitates creation of small molecule drugs for disease treatment.
Enables development of biologics for neurodegenerative therapies.
People of AC Immune
Unlock access to complete
Unlock access to complete
Funding Insights of AC Immune
AC Immune has successfully raised a total of $119.82M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AC Immune
AC Immune has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, The Michael J. Fox Foundation and BVF Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US private equity investments are managed by BVF Partners.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Operates as an employee-owned hedge fund focused on long/short equity strategies.
|
Locked | Locked | Locked |
Investor details for AC Immune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AC Immune
Investment portfolio details for AC Immune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AC Immune
Detailed financials for AC Immune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ac Immune Comparisons
Peer comparison for AC Immune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AC Immune
AC Immune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Vir Biotechnology, Cidara Therapeutics, BioNTech and Decibel Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Medicines are developed to protect, repair, and restore hearing capacity.
|
|
| Locked | Locked | Locked |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
Detailed competitors of AC Immune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ac Immune
Complete news archive for AC Immune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AC Immune
AC Immune was founded in 2003.
AC Immune is headquartered in Lausanne, Switzerland. It is registered at Lausanne, Vaud, Switzerland.
Andrea Pfeifer is the current CEO of AC Immune.
AC Immune is a funded company, having raised a total of $119.82M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at AC Immune is 172.
Annual revenue of AC Immune is $31.01M as on Dec 31, 2024.
AC Immune was founded in 2003 in Lausanne, Switzerland, within the biotechnology sector. Focus is placed on developing antibodies, small molecules, and vaccines targeting Alzheimers disease, Parkinsons, Down syndrome, and glaucoma. A diversified pipeline is maintained, supported by technology platforms such as SupraAntigen for diagnostics and biologics, and Morphomer for small molecule drugs. Operations emphasize neurodegenerative disorders through research and therapeutic innovation.
AC Immune's top competitors include BeiGene, BioNTech and Decibel Therapeutics.
AC Immune offers Active Immunotherapies, Morphomer Platform, and Supraantigen Platform.
Yes, AC Immune is publicly traded on NASDAQ under the ticker symbol ACIU.
AC Immune has 5 investors. Key investors include Lilly, The Michael J. Fox Foundation, BVF Partners, Avidity Partners, and Redmile Group.
The ticker symbol of AC Immune is ACIU on NASDAQ.